Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease.

Mov Disord

Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, Florida 33612, USA.

Published: January 2006

We performed a double-blind randomized placebo-controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS).

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.20666DOI Listing

Publication Analysis

Top Keywords

tegaserod zelnorm
8
parkinson's disease
8
zelnorm treatment
4
treatment constipation
4
constipation parkinson's
4
disease performed
4
performed double-blind
4
double-blind randomized
4
randomized placebo-controlled
4
placebo-controlled pilot
4

Similar Publications

In the military, combat wound infections can progress rapidly to life-threatening sepsis. The discovery of effective small-molecule drugs to prevent and/or treat sepsis is a priority. To identify potential sepsis drug candidates, we used an optimized larval zebrafish model of endotoxicity/sepsis to screen commercial libraries of drugs approved by the U.

View Article and Find Full Text PDF
Article Synopsis
  • Tegaserod is a selective agonist of serotonin receptors and is primarily used to treat bowel diseases, which led researchers to investigate its effects on human cardiac atrial 5-HT receptors.
  • In mice with cardiac-specific overexpression of these receptors, tegaserod demonstrated positive effects on heart muscle contraction and rate, while showing no such effects in normal mice.
  • The study revealed that tegaserod enhances contraction strength in human atrial tissue, particularly when combined with cilostamide, though it acts as a partial agonist compared to serotonin and isoprenaline.
View Article and Find Full Text PDF

Computational pharmacogenomics can potentially identify new indications for already approved drugs and pinpoint compounds with similar mechanism-of-action. Here, we used an integrated drug repositioning approach based on transcriptomics data and structure-based virtual screening to identify compounds with gene signatures similar to three known proteasome inhibitors (PIs; bortezomib, MG-132, and MLN-2238). In vitro validation of candidate compounds was then performed to assess proteasomal proteolytic activity, accumulation of ubiquitinated proteins, cell viability, and drug-induced expression in A375 melanoma and MCF7 breast cancer cells.

View Article and Find Full Text PDF
Article Synopsis
  • Irritable bowel syndrome (IBS) affects 9-23% of people globally, particularly women, and is influenced by various psychosocial and physiological factors, often worsening with stress.
  • The most common type of IBS is IBS-C, leading to the development of new treatments like linaclotide and dietary changes, such as higher fiber and low FODMAP foods, to alleviate symptoms.
  • Experts stress the need for effective treatments as IBS-C significantly impacts quality of life, suggesting potential in multi-drug therapies and further dietary interventions for patients.
View Article and Find Full Text PDF

Small Organic Compounds Mimicking the Effector Domain of Myristoylated Alanine-Rich C-Kinase Substrate Stimulate Female-Specific Neurite Outgrowth.

Int J Mol Sci

September 2023

Keck Center for Collaborative Neuroscience and Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ 08554, USA.

Myristoylated alanine-rich C-kinase substrate (MARCKS) is a critical member of a signaling cascade that influences disease-relevant neural functions such as neural growth and plasticity. The effector domain (ED) of MARCKS interacts with the extracellular glycan polysialic acid (PSA) through the cell membrane to stimulate neurite outgrowth in cell culture. We have shown that a synthetic ED peptide improves functional recovery after spinal cord injury in female but not male mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!